- Thyroid
- Metabolic Reprogramming in Thyroid Cancer
-
Sang-Hyeon Ju, Minchul Song, Joung Youl Lim, Yea Eun Kang, Hyon-Seung Yi, Minho Shong
-
Endocrinol Metab. 2024;39(3):425-444. Published online June 10, 2024
-
DOI: https://doi.org/10.3803/EnM.2023.1802
-
-
Abstract
PDFPubReader ePub
- Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.
- Miscellaneous
- Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
-
Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
-
Endocrinol Metab. 2023;38(6):619-630. Published online November 21, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1814
-
-
3,769
View
-
130
Download
-
2
Web of Science
-
2
Crossref
-
Abstract
PDFPubReader ePub
- Metabolism is a dynamic network of biochemical reactions that support systemic homeostasis amidst changing nutritional, environmental, and physical activity factors. The circulatory system facilitates metabolite exchange among organs, while the endocrine system finely tunes metabolism through hormone release. Endocrine disorders like obesity, diabetes, and Cushing’s syndrome disrupt this balance, contributing to systemic inflammation and global health burdens. They accompany metabolic changes on multiple levels from molecular interactions to individual organs to the whole body. Understanding how metabolic fluxes relate to endocrine disorders illuminates the underlying dysregulation. Cancer is increasingly considered a systemic disorder because it not only affects cells in localized tumors but also the whole body, especially in metastasis. In tumorigenesis, cancer-specific mutations and nutrient availability in the tumor microenvironment reprogram cellular metabolism to meet increased energy and biosynthesis needs. Cancer cachexia results in metabolic changes to other organs like muscle, adipose tissue, and liver. This review explores the interplay between the endocrine system and systems-level metabolism in health and disease. We highlight metabolic fluxes in conditions like obesity, diabetes, Cushing’s syndrome, and cancers. Recent advances in metabolomics, fluxomics, and systems biology promise new insights into dynamic metabolism, offering potential biomarkers, therapeutic targets, and personalized medicine.
-
Citations
Citations to this article as recorded by
- Editorial: Tumor metabolism and programmed cell death
Dan-Lan Pu, Qi-Nan Wu Frontiers in Endocrinology.2024;[Epub] CrossRef - Molecular subtypes of clear cell renal carcinoma based on PCD-related long non-coding RNAs expression: insights into the underlying mechanisms and therapeutic strategies
Han Wang, Yang Liu, Aifa Tang, Xiansheng Zhang European Journal of Medical Research.2024;[Epub] CrossRef
- Thyroid
- Efficient Dissociation Protocol for Generation of Single Cell Suspension from Human Thyroid Tissue for Single Cell RNA Sequencing
-
Shinae Yi, Hyun Jung Kim, Bon Seok Koo, Seong Eun Lee, Jahyun Choi, Yea Eun Kang
-
Endocrinol Metab. 2022;37(4):698-700. Published online August 29, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1536
-
-
2,336
View
-
133
Download
-
1
Web of Science
-
1
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- Unraveling the role of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer by multi-omics analyses
Seong Eun Lee, Seongyeol Park, Shinae Yi, Na Rae Choi, Mi Ae Lim, Jae Won Chang, Ho-Ryun Won, Je Ryong Kim, Hye Mi Ko, Eun-Jae Chung, Young Joo Park, Sun Wook Cho, Hyeong Won Yu, June Young Choi, Min-Kyung Yeo, Boram Yi, Kijong Yi, Joonoh Lim, Jun-Young K Nature Communications.2024;[Epub] CrossRef
- Thyroid
- Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
-
Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
-
Endocrinol Metab. 2022;37(1):53-61. Published online February 28, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1402
-
-
4,430
View
-
194
Download
-
1
Web of Science
-
2
Crossref
-
Abstract
PDFPubReader ePub
- Cancer therapies targeting genetic alterations are a topic of great interest in the field of thyroid cancer, which frequently harbors mutations in the RAS, RAF, and RET genes. Unfortunately, U.S. Food and Drug Administration-approved BRAF inhibitors have relatively low therapeutic efficacy against BRAF-mutant thyroid cancer; in addition, the cancer often acquires drug resistance, which prevents effective treatment. Recent advances in genomics and transcriptomics are leading to a more complete picture of the range of mutations, both driver and messenger, present in thyroid cancer. Furthermore, our understanding of cancer suggests that oncogenic mutations drive tumorigenesis and induce rewiring of cancer cell metabolism, which promotes survival of mutated cells. Synthetic lethality (SL) is a method of neutralizing mutated genes that were previously considered untargetable by traditional genotype-targeted treatments. Because these metabolic events are specific to cancer cells, we have the opportunity to develop new therapies that target tumor cells specifically without affecting healthy tissue. Here, we describe developments in metabolism-based cancer therapy, focusing on the concept of metabolic SL in thyroid cancer. Finally, we discuss the essential implications of metabolic reprogramming and its role in the future direction of SL for thyroid cancer.
-
Citations
Citations to this article as recorded by
- Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park Endocrinology and Metabolism.2023; 38(6): 619. CrossRef - The Role of De novo Serine Biosynthesis from Glucose in Papillary Thyroid Cancer
Seong Eun Lee, Na Rae Choi, Jin-Man Kim, Mi Ae Lim, Bon Seok Koo, Yea Eun Kang International Journal of Thyroidology.2023; 16(2): 175. CrossRef
- Miscellaneous
- Corrigendum: Correction of Acknowledgments. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
-
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
-
Endocrinol Metab. 2022;37(1):181-182. Published online February 28, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.104
-
Corrects: Endocrinol Metab 2021;36(2):359
-
3,353
View
-
115
Download
-
1
Web of Science
-
1
Crossref
-
PDFPubReader ePub
-
Citations
Citations to this article as recorded by
- Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho Diabetes, Obesity and Metabolism.2024; 26(1): 108. CrossRef
- Thyroid
- Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea
-
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
-
Endocrinol Metab. 2021;36(5):1078-1085. Published online October 28, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.1151
-
-
4,691
View
-
120
Download
-
5
Web of Science
-
5
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.
Methods This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.
Results The mean age of the 97 patients included in the study was 50.3 years, and 26.8% were male. The mean size of the primary tumor was 3.2±1.8 cm, and three (3.1%) patients had distant metastasis at initial diagnosis. Ultrasonographic findings were available for 73 patients; the number of nodules with low-, intermediate-, and high suspicion was 28 (38.4%), 27 (37.0%), and 18 (24.7%), respectively, based on the Korean-Thyroid Imaging Reporting and Data System. Preoperatively, follicular neoplasm (FN) or suspicion for FN accounted for 65.2% of the cases according to the Bethesda category, and 13% had malignancy or suspicious for malignancy. During a median follow-up of 8.5 years, eight (8.2%) patients had persistent/recurrent disease, and none died of HCC. Older age, gross extrathyroidal extension (ETE), and widely invasive types of tumors were significantly associated with distant metastasis (all P<0.01). Gross ETE (hazard ratio [HR], 27.7; 95% confidence interval [CI], 2.2 to 346.4; P=0.01) and widely invasive classification (HR, 6.5; 95% CI, 1.1 to 39.4; P=0.04) were independent risk factors for poor disease-free survival (DFS).
Conclusion The long-term prognosis of HCC is relatively favorable in South Korea from this study, although this is not a nation-wide data, and gross ETE and widely invasive cancer are significant prognostic factors for DFS. The diagnosis of HCC by ultrasonography and cytopathology remains challenging.
-
Citations
Citations to this article as recorded by
- Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
Lindsay A. Bischoff, Ian Ganly, Laura Fugazzola, Erin Buczek, William C. Faquin, Bryan R. Haugen, Bryan McIver, Caitlin P. McMullen, Kate Newbold, Daniel J. Rocke, Marika D. Russell, Mabel Ryder, Peter M. Sadow, Eric Sherman, Maisie Shindo, David C. Shonk JAMA Otolaryngology–Head & Neck Surgery.2024; 150(3): 265. CrossRef - Oncocytic carcinoma of the thyroid: Conclusions from a 20‐year patient cohort
Nelson R. Gruszczynski, Shahzeb S. Hasan, Ana G. Brennan, Julian De La Chapa, Adithya S. Reddy, David N. Martin, Prem P. Batchala, Edward B. Stelow, Eric M. Dowling, Katherine L. Fedder, Jonathan C. Garneau, David C. Shonka Head & Neck.2024; 46(8): 2042. CrossRef - Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report
Xiqian Wang, Yingao Liu, Lijie Chen, Jie Zhang, Ruoyu Jiang, Lei Zhang, Han Yan, Jie Zhang Frontiers in Endocrinology.2024;[Epub] CrossRef - Hurthle cell carcinoma - a rare variant of thyroid malignancy: a case report
Yuvraj Adhikari, Anupama Marasini, Nawaraj Adhikari, Laxman Dutta Paneru, Binit Upadhaya Regmi, Manita Raut Annals of Medicine & Surgery.2023;[Epub] CrossRef - Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
Costanza Chiapponi, Milan J.M. Hartmann, Matthias Schmidt, Michael Faust, Christiane J. Bruns, Anne M. Schultheis, Hakan Alakus Frontiers in Endocrinology.2022;[Epub] CrossRef
- Thyroid
- A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
-
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka Hee Yi, Sue K. Park, Eun-Jae Jung, June Young Choi, Ja Seong Bae, Joon Hwa Hong, Kee-Hyun Nam, Young Ki Lee, Hyeong Won Yu, Sujeong Go, Young Mi Kang, MASTER study group
-
Endocrinol Metab. 2021;36(3):574-581. Published online May 26, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.943
-
-
7,249
View
-
295
Download
-
11
Web of Science
-
14
Crossref
-
Abstract
PDFPubReader ePub
- Background
Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
-
Citations
Citations to this article as recorded by
- Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef - Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: The MASTER study
Da Beom Heo, Ho-Ryun Won, Kyung Tae, Yea Eun Kang, Eonju Jeon, Yong Bae Ji, Jae Won Chang, June Young Choi, Hyeong Won Yu, Eu Jeong Ku, Eun Kyung Lee, Mijin Kim, Jun-Ho Choe, Bon Seok Koo Surgery.2024; 175(4): 1049. CrossRef - Dynamic Changes in Treatment Response af-ter 131I in Differentiated Thyroid Cancer and Their Relationship with Recurrence Risk Stratification and TNM Staging
璐 狄 Advances in Clinical Medicine.2024; 14(03): 1083. CrossRef - Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024
Mijin Kim, Ji-In Bang, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Youngduk Seo, Young Shin Song, So Won Oh, Sang-Woo Lee, Eun Kyung Lee, Ji Ye Lee, Dong-Jun Lim, Ari Chong, Yun Jae Chung, Chae Moon Hong, Min Kyoung Lee, Bo Hyun Kim International Journal of Thyroidology.2024; 17(1): 115. CrossRef - Levothyroxine Dosage and the Increased Risk of Second Primary Malignancy in Thyroid Cancer Survivors
Young Joo Park Clinical Thyroidology®.2024; 36(7): 258. CrossRef - Prognostic Implications of Maintaining the Target Thyroid-Stimulating Hormone Status Based on the 2015 American Thyroid Association Guidelines in Patients with Low-Risk Papillary Thyroid Carcinoma after Lobectomy: A 5-Year Landmark Analysis
Ye Won Jeon, Young Jin Suh, Seung Taek Lim Cancers.2024; 16(19): 3253. CrossRef - ASO Author Reflections: Active Surveillance may be Possible in Patients with T1b Papillary Thyroid Carcinoma Over 55 Years of Age Without High-Risk Features on Preoperative Examinations
Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2023; 30(4): 2254. CrossRef - Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar Otolaryngology–Head and Neck Surgery.2023; 168(4): 745. CrossRef - Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis
Timothy M Ullmann, Maria Papaleontiou, Julie Ann Sosa The Journal of Clinical Endocrinology & Metabolism.2023; 108(2): 271. CrossRef - Age-Dependent Clinicopathological Characteristics of Patients with T1b Papillary Thyroid Carcinoma: Implications for the Possibility of Active Surveillance
Ho-Ryun Won, Eonju Jeon, Da Beom Heo, Jae Won Chang, Minho Shong, Je Ryong Kim, Hyemi Ko, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Kyong Hye Joung, Ji Min Kim, Younju Lee, Sung-Woo Kim, Young Ju Jeong, Yong Bae Ji, Kyung Tae, Bon Seok Koo Annals of Surgical Oncology.2023; 30(4): 2246. CrossRef - Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study
Mijin Kim, Yae Eun Kang, Young Joo Park, Bon Seok Koo, Eu Jeong Ku, June Young Choi, Eun Kyung Lee, Bo Hyun Kim Endocrine.2023; 82(1): 134. CrossRef - Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
Benjamin J. Gigliotti, Sina Jasim Endocrine.2023; 83(2): 251. CrossRef - Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma
Mi Rye Bae, Sung Hoon Nam, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim Endocrine.2022; 75(2): 487. CrossRef - The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park Endocrinology and Metabolism.2021; 36(4): 725. CrossRef
- Diabetes, Obesity and Metabolism
- Expression of LONP1 Is High in Visceral Adipose Tissue in Obesity, and Is Associated with Glucose and Lipid Metabolism
-
Ju Hee Lee, Saet-Byel Jung, Seong Eun Lee, Ji Eun Kim, Jung Tae Kim, Yea Eun Kang, Seul Gi Kang, Hyon-Seung Yi, Young Bok Ko, Ki Hwan Lee, Bon Jeong Ku, Minho Shong, Hyun Jin Kim
-
Endocrinol Metab. 2021;36(3):661-671. Published online June 22, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.1023
-
-
5,190
View
-
160
Download
-
8
Web of Science
-
7
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
The nature and role of the mitochondrial stress response in adipose tissue in relation to obesity are not yet known. To determine whether the mitochondrial unfolded protein response (UPRmt) in adipose tissue is associated with obesity in humans and rodents.
Methods Visceral adipose tissue (VAT) was obtained from 48 normoglycemic women who underwent surgery. Expression levels of mRNA and proteins were measured for mitochondrial chaperones, intrinsic proteases, and components of electron-transport chains. Furthermore, we systematically analyzed metabolic phenotypes with a large panel of isogenic BXD inbred mouse strains and Genotype-Tissue Expression (GTEx) data.
Results In VAT, expression of mitochondrial chaperones and intrinsic proteases localized in inner and outer mitochondrial membranes was not associated with body mass index (BMI), except for the Lon protease homolog, mitochondrial, and the corresponding gene LONP1, which showed high-level expression in the VAT of overweight or obese individuals. Expression of LONP1 in VAT positively correlated with BMI. Analysis of the GTEx database revealed that elevation of LONP1 expression is associated with enhancement of genes involved in glucose and lipid metabolism in VAT. Mice with higher Lonp1 expression in adipose tissue had better systemic glucose metabolism than mice with lower Lonp1 expression.
Conclusion Expression of mitochondrial LONP1, which is involved in the mitochondrial quality control stress response, was elevated in the VAT of obese individuals. In a bioinformatics analysis, high LONP1 expression in VAT was associated with enhanced glucose and lipid metabolism.
-
Citations
Citations to this article as recorded by
- LONP1 ameliorates liver injury and improves gluconeogenesis dysfunction in acute-on-chronic liver failure
Muchen Wu, Jing Wu, Kai Liu, Minjie Jiang, Fang Xie, Xuehong Yin, Jushan Wu, Qinghua Meng Chinese Medical Journal.2024; 137(2): 190. CrossRef - Tissue‐specific roles of mitochondrial unfolded protein response during obesity
Fernanda S. Carneiro, Carlos K. Katashima, Joshua D. Dodge, Dennys E. Cintra, José Rodrigo Pauli, Adelino S. R. Da Silva, Eduardo R. Ropelle Obesity Reviews.2024;[Epub] CrossRef - Mitochondrial quality control proteases and their modulation for cancer therapy
Jiangnan Zhang, Wenliang Qiao, Youfu Luo Medicinal Research Reviews.2023; 43(2): 399. CrossRef - Effects of Obesity and Calorie Restriction on Cancer Development
Ekaterina Sergeeva, Tatiana Ruksha, Yulia Fefelova International Journal of Molecular Sciences.2023; 24(11): 9601. CrossRef - Mitochondrial Dysfunction Associated with mtDNA in Metabolic Syndrome and Obesity
Natalia Todosenko, Olga Khaziakhmatova, Vladimir Malashchenko, Kristina Yurova, Maria Bograya, Maria Beletskaya, Maria Vulf, Natalia Gazatova, Larisa Litvinova International Journal of Molecular Sciences.2023; 24(15): 12012. CrossRef - Down‐regulation of Lon protease 1 lysine crotonylation aggravates mitochondrial dysfunction in polycystic ovary syndrome
Yuan Xie, Shuwen Chen, Zaixin Guo, Ying Tian, Xinyu Hong, Penghui Feng, Qiu Xie, Qi Yu MedComm.2023;[Epub] CrossRef - The mitochondrial unfolded protein response: A multitasking giant in the fight against human diseases
Zixin Zhou, Yumei Fan, Ruikai Zong, Ke Tan Ageing Research Reviews.2022; 81: 101702. CrossRef
- Clinical Study
- Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
-
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
-
Endocrinol Metab. 2021;36(2):359-364. Published online March 23, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.890
-
Correction in: Endocrinol Metab 2022;37(1):181
-
6,467
View
-
213
Download
-
17
Web of Science
-
18
Crossref
-
Abstract
PDFPubReader ePub
- Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.
-
Citations
Citations to this article as recorded by
- Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park Endocrinology and Metabolism.2024; 39(1): 47. CrossRef - It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
Kyeong Jin Kim Endocrinology and Metabolism.2024; 39(1): 95. CrossRef - Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang Endocrinology and Metabolism.2024; 39(1): 152. CrossRef - Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang Endocrinology and Metabolism.2024; 39(1): 152. CrossRef - Comparison of Patient Reported Outcomes between Active surveillance and Immediate Lobectomy in Patients with Low-risk Papillary Thyroid Microcarcinoma: Initial Findings from the KoMPASS cohort
Min Joo Kim, Hojeong Won, Won Bae Kim, Eun Kyung Lee, Chang Yoon Lee, Sun Wook Cho, Han-Sang Baek, Yong Sang Lee, Yae Eun Kang, Sun Wook Kim, Ho Cheol Kang, Jeongmin Lee, Mijin Kim, Min Ji Jeon, Jae Hoon Moon Thyroid®.2024;[Epub] CrossRef - Thyroid‐Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low‐Risk Papillary Thyroid Microcarcinoma in Adults
Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura World Journal of Surgery.2023; 47(2): 392. CrossRef - Thyroid FNA cytology: The Eastern versus Western perspectives
Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari Cancer Cytopathology.2023; 131(7): 415. CrossRef - To Screen or Not to Screen?
Do Joon Park Endocrinology and Metabolism.2023; 38(1): 69. CrossRef - Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park Endocrinology and Metabolism.2023; 38(1): 93. CrossRef - Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience
Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Akihiro Miya, Naoyoshi Onoda, Minoru Kihara, Takuya Higashiyama, Hiroo Masuoka, Shiori Kawano, Takahiro Sasaki, Mitsushige Nishikawa, Shuji Fukata, Takashi Akamizu, Mitsuru Ito, Eijun Nishihara, Mako Hisakad Thyroid®.2023; 33(7): 817. CrossRef - Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status
Masashi Yamamoto, Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki, Takumi Kudo Thyroid®.2023; 33(10): 1182. CrossRef - Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim Journal of Korean Medical Science.2023;[Epub] CrossRef - Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
Ik Beom Shin, Do Hoon Koo, Dong Sik Bae Clinical Medicine Insights: Oncology.2023;[Epub] CrossRef - Thermal Ablation for Papillary Thyroid Microcarcinoma Located in The Isthmus: a Study With 3 Years Of Follow-Up
Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang Future Oncology.2022; 18(4): 471. CrossRef - Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara Thyroid.2022; 32(4): 397. CrossRef - Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo Journal of Clinical Medicine.2021; 10(16): 3569. CrossRef - Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim Cancer Management and Research.2021; Volume 13: 6721. CrossRef - Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim Endocrinology and Metabolism.2021; 36(4): 717. CrossRef
- Clinical Study
- Genetic Analysis of CLCN7 in an Old Female Patient with Type II Autosomal Dominant Osteopetrosis
-
Seon Young Kim, Younghak Lee, Yea Eun Kang, Ji Min Kim, Kyong Hye Joung, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong, Hyon-Seung Yi
-
Endocrinol Metab. 2018;33(3):380-386. Published online September 18, 2018
-
DOI: https://doi.org/10.3803/EnM.2018.33.3.380
-
-
4,662
View
-
61
Download
-
2
Web of Science
-
2
Crossref
-
Abstract
PDFPubReader ePub
- Background
Type II autosomal dominant osteopetrosis (ADO II) is a rare genetically heterogeneous disorder characterized by osteosclerosis and increased bone mass, predominantly involving spine, pelvis, and skull. It is closely related to functional defect of osteoclasts caused by chloride voltage-gated channel 7 (CLCN7) gene mutations. In this study, we aimed to identify the pathogenic mutation in a Korean patient with ADO II using whole exome sequencing. MethodsWe evaluated the clinical, biochemical, and radiographic analysis of a 68-year-old woman with ADO II. We also performed whole exome sequencing to identify pathogenic mutation of a rare genetic disorder of the skeleton. Moreover, a polymorphism phenotyping program, Polymorphism Phenotyping v2 (PolyPhen-2), was used to assess the effect of the identified mutation on protein function. ResultsWhole exome sequencing using peripheral leukocytes revealed a heterozygous c.296A>G missense mutation in the CLCN7 gene. The mutation was also confirmed using Sanger sequencing. The mutation c.296A>G was regarded to have a pathogenic effect by PolyPhen-2 software. ConclusionWe detect a heterozygous mutation in CLCN7 gene of a patient with ADO II, which is the first report in Korea. Our present findings suggest that symptoms and signs of ADO II patient having a c.296A>G mutation in CLCN7 may appear at a very late age. The present study would also enrich the database of CLCN7 mutations and improve our understanding of ADO II.
-
Citations
Citations to this article as recorded by
- Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report
Xiu-Li Song, Li-Yuan Peng, Dao-Wen Wang, Hong Wang World Journal of Clinical Cases.2022; 10(20): 6936. CrossRef - Magnetic resonance findings in a Cavalier King Charles spaniel with osteopetrosis, Chiari‐like malformation and syringomyelia
Ricardo Fernandes, C J Jordan, Colin Driver Veterinary Record Case Reports.2019;[Epub] CrossRef
- Clinical Study
- The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome
-
Younghak Lee, Hyon-Seung Yi, Hae Ri Kim, Kyong Hye Joung, Yea Eun Kang, Ju Hee Lee, Koon Soon Kim, Hyun Jin Kim, Bon Jeong Ku, Minho Shong
-
Endocrinol Metab. 2017;32(3):353-359. Published online September 18, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.3.353
-
-
8,999
View
-
48
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
- Background
Cushing syndrome is characterized by glucose intolerance, cardiovascular disease, and an enhanced systemic inflammatory response caused by chronic exposure to excess cortisol. Eosinopenia is frequently observed in patients with adrenal Cushing syndrome, but the relationship between the eosinophil count in peripheral blood and indicators of glucose level in patients with adrenal Cushing syndrome has not been determined. MethodsA retrospective study was undertaken of the clinical and laboratory findings of 40 patients diagnosed with adrenal Cushing syndrome at Chungnam National University Hospital from January 2006 to December 2016. Clinical characteristics, complete blood cell counts with white blood cell differential, measures of their endocrine function, description of imaging studies, and pathologic findings were obtained from their medical records. ResultsEosinophil composition and count were restored by surgical treatment of all of the patients with adrenal Cushing disease. The eosinophil count was inversely correlated with serum and urine cortisol, glycated hemoglobin, and inflammatory markers in the patients with adrenal Cushing syndrome. ConclusionSmaller eosinophil populations in patients with adrenal Cushing syndrome tend to be correlated with higher levels of blood sugar and glycated hemoglobin. This study suggests that peripheral blood eosinophil composition or count may be associated with serum glucose levels in patients with adrenal Cushing syndrome.
-
Citations
Citations to this article as recorded by
- Association between Eosinophil Count and Cortisol Concentrations in Equids Admitted in the Emergency Unit with Abdominal Pain
María Villalba-Orero, María Dolores Contreras-Aguilar, Jose Joaquín Cerón, Beatriz Fuentes-Romero, Marta Valero-González, María Martín-Cuervo Animals.2024; 14(1): 164. CrossRef - Inverse relationship between eosinophil profiles and serum glucose concentration in dogs with naturally occurring hypercortisolism
Jimin Oh, Dohee Lee, Taesik Yun, Yoonhoi Koo, Yeon Chae, Mhan-Pyo Yang, Byeong-Teck Kang, Hakhyun Kim Domestic Animal Endocrinology.2022; 80: 106727. CrossRef - Serum Cortisol and Its Correlation with Leucocyte Profile and Circulating Lipids in Donkeys (Equus asinus)
Daniela Alberghina, Alessandra Statelli, Vincenzo Monteverde, Irene Vazzana, Giuseppe Cascone, Michele Panzera Animals.2022; 12(7): 841. CrossRef - Changes in leukocytes and CRP in different stages of major depression
Deepti Singh, Paul C. Guest, Henrik Dobrowolny, Veronika Vasilevska, Gabriela Meyer-Lotz, Hans-Gert Bernstein, Katrin Borucki, Alexandra Neyazi, Bernhard Bogerts, Roland Jacobs, Johann Steiner Journal of Neuroinflammation.2022;[Epub] CrossRef - HIF1α is a direct regulator of steroidogenesis in the adrenal gland
Deepika Watts, Johanna Stein, Ana Meneses, Nicole Bechmann, Ales Neuwirth, Denise Kaden, Anja Krüger, Anupam Sinha, Vasileia Ismini Alexaki, Luis Gustavo Perez-Rivas, Stefan Kircher, Antoine Martinez, Marily Theodoropoulou, Graeme Eisenhofer, Mirko Peitz Cellular and Molecular Life Sciences.2021; 78(7): 3577. CrossRef - The Immune System in Cushing’s Syndrome
Valeria Hasenmajer, Emilia Sbardella, Francesca Sciarra, Marianna Minnetti, Andrea M. Isidori, Mary Anna Venneri Trends in Endocrinology & Metabolism.2020; 31(9): 655. CrossRef
- Clinical Study
- The Role of Circulating Slit2, the One of the Newly Batokines, in Human Diabetes Mellitus
-
Yea Eun Kang, Sorim Choung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
-
Endocrinol Metab. 2017;32(3):383-388. Published online September 18, 2017
-
DOI: https://doi.org/10.3803/EnM.2017.32.3.383
-
-
4,337
View
-
54
Download
-
19
Web of Science
-
18
Crossref
-
Abstract
PDFPubReader
- Background
Slit2 is a new secreted protein from adipose tissue that improves glucose hemostasis in mice; however, there is no study about the serum levels and precise role of Slit2 in human. The aim of this study is to explore the serum level of Slit2 in human, and to identify the role of Slit2 in diabetes mellitus (DM). MethodsThe participants of this study consist of 38 subjects with newly diagnosed DM, and 75 healthy subjects as a control group. Serum Slit2 levels were measured using an enzyme-linked immunosorbent assay. Relationship between circulating Slit2 and diabetic related factors was investigated in diabetic group compared with non-diabetic group. Additionally, the correlations between the serum level of Slit2 and diverse metabolic parameters were analyzed. ResultsCirculating Slit2 level was more decreased in diabetic group than in control group, but there was no significant difference statistically. Interestingly, serum levels of Slit2 were significantly negatively correlated to the serum concentrations of fasting glucose (coefficient r=–0.246, P=0.008), the serum concentrations of postprandial glucose (coefficient r=–0.233, P=0.017), and glycosylated hemoglobin (HbA1c; coefficient r=–0.357, P<0.001). ConclusionFrom our study, the first report of circulating Slit2 levels in human, circulating Slit2 level significantly negatively correlated with serum glucose and HbA1c. Our results suggest that the circulating Slit2 may play a role in maintainence of glucose homeostasis in human, even though exact contribution and mechanism are not yet known.
-
Citations
Citations to this article as recorded by
- Brown adipose tissue-derived metabolites and their role in regulating metabolism
Khanyisani Ziqubu, Phiwayinkosi V. Dludla, Sihle E. Mabhida, Babalwa U. Jack, Susanne Keipert, Martin Jastroch, Sithandiwe E. Mazibuko-Mbeje Metabolism.2024; 150: 155709. CrossRef - An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications
Zeinab Ghesmati, Mohsen Rashid, Shabnam Fayezi, Frank Gieseler, Effat Alizadeh, Masoud Darabi Reviews in Endocrine and Metabolic Disorders.2024; 25(2): 279. CrossRef - The integrated bioinformatic analysis identifies immune microenvironment-related potential biomarkers for patients with gestational diabetes mellitus
Jie-ling Chen, Hui-fang Dai, Xin-chen Kan, Jie Wu, Hong-Wu Chen Frontiers in Immunology.2024;[Epub] CrossRef - Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases
Shaghayegh Hemat Jouy, Sukrutha Mohan, Giorgia Scichilone, Amro Mostafa, Abeer M. Mahmoud Biomedicines.2024; 12(9): 2129. CrossRef - Adipokines from white adipose tissue in regulation of whole body energy homeostasis
Bijayashree Sahu, Naresh C. Bal Biochimie.2023; 204: 92. CrossRef - The Role of Slit-2 in Gestational Diabetes Mellitus and Its Effect on Pregnancy Outcome
Yan Wang, Shihua Zhao, Wei Peng, Ying Chen, Jingwei Chi, Kui Che, Yangang Wang Frontiers in Endocrinology.2022;[Epub] CrossRef - The Heartwarming Effect of Brown Adipose Tissue
Kelsey M. Pinckard, Kristin I. Stanford Molecular Pharmacology.2022; 102(1): 39. CrossRef - New players of the adipose secretome: Therapeutic opportunities and challenges
Laetitia Coassolo, Niels Banhos Dannieskiold-Samsøe, Meng Zhao, Hobson Allen, Katrin J. Svensson Current Opinion in Pharmacology.2022; 67: 102302. CrossRef - Serum CD14 concentration is associated with obesity and insulin resistance in non-diabetic individuals
Yea Eun Kang, Kyong Hye Joung, Ji Min Kim, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku Journal of International Medical Research.2022; 50(10): 030006052211300. CrossRef - Brown/Beige adipose tissues and the emerging role of their secretory factors in improving metabolic health: The batokines
Bilal Ahmad, Muhammad Sufyan Vohra, Mansab Ali Saleemi, Christopher J. Serpell, Isabel Lim Fong, Eng Hwa Wong Biochimie.2021; 184: 26. CrossRef - Thermogenic Fat: Development, Physiological Function, and Therapeutic Potential
Bruna B. Brandão, Ankita Poojari, Atefeh Rabiee International Journal of Molecular Sciences.2021; 22(11): 5906. CrossRef - Brown Adipose Crosstalk in Tissue Plasticity and Human Metabolism
Camilla Scheele, Christian Wolfrum Endocrine Reviews.2020; 41(1): 53. CrossRef - Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence
Michael Luong, Ying Wang, Stephen P. Berasi, Janet E. Buhlmann, Hongying Yang, Boris Gorovits The AAPS Journal.2020;[Epub] CrossRef - Brown and beige fat: From molecules to physiology and pathophysiology
Stefania Carobbio, Anne-Claire Guénantin, Isabella Samuelson, Myriam Bahri, Antonio Vidal-Puig Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.2019; 1864(1): 37. CrossRef - Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance
Yea Eun Kang, Ji Min Kim, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku Diabetes & Metabolism Journal.2019; 43(3): 368. CrossRef - Deletion of Robo4 prevents high‐fat diet‐induced adipose artery and systemic metabolic dysfunction
Tam T. T. Phuong, Ashley E. Walker, Grant D. Henson, Daniel R. Machin, Dean Y. Li, Anthony J. Donato, Lisa A. Lesniewski Microcirculation.2019;[Epub] CrossRef - Adipose Tissue-Derived Signatures for Obesity and Type 2 Diabetes: Adipokines, Batokines and MicroRNAs
Min-Woo Lee, Mihye Lee, Kyoung-Jin Oh Journal of Clinical Medicine.2019; 8(6): 854. CrossRef - The role of brown and beige adipose tissue in glycaemic control
Katarina Klepac, Anastasia Georgiadi, Matthias Tschöp, Stephan Herzig Molecular Aspects of Medicine.2019; 68: 90. CrossRef
- Obesity and Metabolism
- Plasma Adiponectin Levels in Elderly Patients with Prediabetes
-
Si Eun Kong, Yea Eun Kang, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
-
Endocrinol Metab. 2015;30(3):326-333. Published online August 4, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.3.326
-
-
3,660
View
-
37
Download
-
7
Web of Science
-
3
Crossref
-
Abstract
PDFPubReader
- Background
The significance of adiponectin levels in elderly individuals with prediabetes has yet to be determined. Thus, the present study was performed to evaluate the relationships between adiponectin levels and anthropometric variables, body composition parameters, insulin sensitivity, and lipid profiles in elderly prediabetic patients. MethodsThe present study included 120 subjects with prediabetes who were >65 years of age and were selected from among 1,993 subjects enrolled in the Korea Rural Genomic Cohort Study. All subjects underwent a 75 g oral glucose tolerance test and tests for measurement of insulin sensitivity. All diagnoses of prediabetes satisfied the criteria of the American Diabetes Association. ResultsPlasma adiponectin levels were lower in elderly prediabetic subjects than elderly subjects with normal glucose tolerance (P<0.01) as well as in elderly prediabetic patients with metabolic syndrome (MetS) than in those without MetS (P<0.02). When the subjects were categorized into two groups according to plasma adiponectin levels, the waist-to-hip ratio and 2-hour insulin levels were significantly lower in individuals with high plasma adiponectin levels than in those with low plasma adiponectin levels. Additionally, the plasma adiponectin levels of elderly prediabetic subject were inversely correlated with body mass index (BMI), waist circumference (WC), waist-to-hip ratio, visceral fat, visceral fat ratio, and 2-hour insulin levels. ConclusionThe present findings demonstrated that the major factors correlated with adiponectin levels in elderly prediabetic subjects were BMI, WC, waist-to-hip ratio, visceral fat, visceral fat ratio, and 2-hour insulin levels.
-
Citations
Citations to this article as recorded by
- Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study
Mohammad Muzaffar Mir, Rashid Mir, Mushabab Ayed Abdullah Alghamdi, Javed Iqbal Wani, Zia Ul Sabah, Mohammed Jeelani, Vijaya Marakala, Shahzada Khalid Sohail, Mohamed O’haj, Muffarah Hamid Alharthi, Mohannad Mohammad S. Alamri Journal of Personalized Medicine.2022; 12(5): 735. CrossRef - Postloading insulinemia is independently associated with arterial stiffness in young Japanese persons
Norimitsu Murai, Naoko Saito, Sayuri Nii, Yuto Nishikawa, Asami Suzuki, Eriko Kodama, Tatsuya Iida, Kentaro Mikura, Hideyuki Imai, Mai Hashizume, Yasuyoshi Kigawa, Rie Tadokoro, Chiho Sugisawa, Kei Endo, Toru Iizaka, Fumiko Otsuka, Shun Ishibashi, Shoichi Hypertension Research.2021; 44(11): 1515. CrossRef - Association of Adiponectin and rs1501299 of the ADIPOQ Gene with Prediabetes in Jordan
Mahmoud A. Alfaqih, Faheem Al-Mughales, Othman Al-Shboul, Mohammad Al Qudah, Yousef S. Khader, Muhammad Al-Jarrah Biomolecules.2018; 8(4): 117. CrossRef
- Thyroid
- Mitochondrial Energy Metabolism and Thyroid Cancers
-
Junguee Lee, Joon Young Chang, Yea Eun Kang, Shinae Yi, Min Hee Lee, Kyong Hye Joung, Kun Soon Kim, Minho Shong
-
Endocrinol Metab. 2015;30(2):117-123. Published online June 30, 2015
-
DOI: https://doi.org/10.3803/EnM.2015.30.2.117
-
-
4,902
View
-
54
Download
-
16
Web of Science
-
16
Crossref
-
Abstract
PDFPubReader
Primary thyroid cancers including papillary, follicular, poorly differentiated, and anaplastic carcinomas show substantial differences in biological and clinical behaviors. Even in the same pathological type, there is wide variability in the clinical course of disease progression. The molecular carcinogenesis of thyroid cancer has advanced tremendously in the last decade. However, specific inhibition of oncogenic pathways did not provide a significant survival benefit in advanced progressive thyroid cancer that is resistant to radioactive iodine therapy. Accumulating evidence clearly shows that cellular energy metabolism, which is controlled by oncogenes and other tumor-related factors, is a critical factor determining the clinical phenotypes of cancer. However, the role and nature of energy metabolism in thyroid cancer remain unclear. In this article, we discuss the role of cellular energy metabolism, particularly mitochondrial energy metabolism, in thyroid cancer. Determining the molecular nature of metabolic remodeling in thyroid cancer may provide new biomarkers and therapeutic targets that may be useful in the management of refractory thyroid cancers.
-
Citations
Citations to this article as recorded by
- Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review
Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Anna Popławska-Kita Frontiers in Pharmacology.2024;[Epub] CrossRef - Liquid Biopsy as a Method for Minimally Invasive Diagnosis of Thyroid Cancer
Tagir I. Rakhmatullin, Mark Jain, Larisa M. Samokhodskaya, Vladimir A. Zhivotov Journal of Clinical Practice.2023; 14(3): 69. CrossRef - Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong Endocrinology and Metabolism.2022; 37(1): 53. CrossRef - Monensin Inhibits Anaplastic Thyroid Cancer via Disrupting Mitochondrial Respiration
and AMPK/mTOR Signaling
Yanli Li, Qianshu Sun, Sisi Chen, Xiongjie Yu, Hongxia Jing Anti-Cancer Agents in Medicinal Chemistry.2022; 22(14): 2539. CrossRef - Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness
Yea Eun Kang, Jin Man Kim, Mi Ae Lim, Seong Eun Lee, Shinae Yi, Jung Tae Kim, Chan Oh, Lihua Liu, Yanli Jin, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Jeong Ho Lee, Hyun Jung Kim, Hyun Yong Koh, Sangmi Jun, Sun Wook Cho, Minho Shong, Bon Seok Koo Thyroid.2021; 31(5): 772. CrossRef - Clinical Significance of the D-Loop Gene Mutation in Mitochondrial DNA in Laryngeal Cancer
Lei Wang, He-Xiang Cheng, Yan-Hui Zhou, Min Ma OncoTargets and Therapy.2021; Volume 14: 3461. CrossRef - Transcriptomic and Genetic Associations between Alzheimer’s Disease, Parkinson’s Disease, and Cancer
Jaume Forés-Martos, Cesar Boullosa, David Rodrigo-Domínguez, Jon Sánchez-Valle, Beatriz Suay-García, Joan Climent, Antonio Falcó, Alfonso Valencia, Joan Anton Puig-Butillé, Susana Puig, Rafael Tabarés-Seisdedos Cancers.2021; 13(12): 2990. CrossRef - KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma
Zheng Wang, Xinguang Qiu, Hao Zhang, Weihan Li Journal of Biochemical and Molecular Toxicology.2020;[Epub] CrossRef - Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma
Ruben D. Addie, Sarantos Kostidis, Willem E. Corver, Jan Oosting, Sepideh Aminzadeh-Gohari, René G. Feichtinger, Barbara Kofler, Mehtap Derya Aydemirli, Martin Giera, Hans Morreau Scientific Reports.2020;[Epub] CrossRef - Inhibition of mitochondrial respiration by tigecycline selectively targets thyroid carcinoma and increases chemosensitivity
Yuehua Wang, Fei Xie, Dejie Chen, Ling Wang Clinical and Experimental Pharmacology and Physiology.2019; 46(10): 890. CrossRef - Investigating Therapeutic Effects of Retinoic Acid on Thyroid Cancer via Protein-Protein Interaction Network Analysis
Majid Rezaei-Tavirani, Mostafa Rezaei-Tavirani, Mona Zamanian Azodi International Journal of Cancer Management.2019;[Epub] CrossRef - CASE REPORT: An Extensively Necrotic Hürthle-Cell Carcinoma Mimicked a Thyroid Abscess
Sanders H. Lin, Shih-Ming Huang, Su-Lin Peng Clinical Thyroidology.2018; 30(11): 529. CrossRef - Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer
Zhuo Lv, Xintong Yan, Liying Lu, Chun Su, Yin He Journal of Bioenergetics and Biomembranes.2018; 50(4): 263. CrossRef - Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma
Xianyin Lai, Christopher B. Umbricht, Kurt Fisher, Justin Bishop, Qiuying Shi, Shaoxiong Chen Journal of Proteomics.2017; 166: 59. CrossRef - Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
Marika H Tesselaar, Johannes W Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga Journal of Molecular Endocrinology.2017; 59(4): R141. CrossRef - Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis
Nurul-Syakima Ab Mutalib, Sri Noraima Othman, Azliana Mohamad Yusof, Shahrun Niza Abdullah Suhaimi, Rohaizak Muhammad, Rahman Jamal PeerJ.2016; 4: e2119. CrossRef
- Bone Metabolism
- A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets
-
Yea Eun Kang, Jun Hwa Hong, Jimin Kim, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku, Koon Soon Kim
-
Endocrinol Metab. 2014;29(2):195-201. Published online June 26, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.2.195
-
-
4,225
View
-
34
Download
-
5
Web of Science
-
4
Crossref
-
Abstract
PDFPubReader
Phosphate regulating gene with homologies to endopeptidases on the X-chromosome (PHEX) is a common cause of X-linked hypophosphatemic (XLH) rickets. Diverse PHEX gene mutations have been reported; however, gene mutations in sporadic rickets are less common than in XLH rickets. Herein, we describe a 50-year-old female patient with sporadic hypophosphatemic rickets harboring a novel splicing-site mutation in the PHEX gene (c.663+1G>A) at the exon 5-intron 5 boundary. The patient had recently suffered from right thigh pain and an aggravated waddling gait. She also presented with very short stature, generalized bone pain, and muscle weakness. Despite low serum phosphate levels, her phosphate reabsorption rate was lower than normal. Additionally, her 1,25-dihydroxyvitamin D3 concentration was lower than normal, although FGF23 level was normal. After treatment with alfacalcidol and elemental phosphate, her rachitic symptoms subsided, and callus formation was observed in the fracture site on the right femur.
-
Citations
Citations to this article as recorded by
- A pathogenic PHEX variant (c.1483-1G>C) in a Korean patient with X-linked hypophosphatemic rickets
In Hwa Jeong, Jae-Ho Yoo, Namhee Kim Annals of Pediatric Endocrinology & Metabolism.2021; 26(2): 130. CrossRef - A novel de novo mosaic mutation in PHEX in a Korean patient with hypophosphatemic rickets
Misun Yang, Jinsup Kim, Aram Yang, Jahyun Jang, Tae Yeon Jeon, Sung Yoon Cho, Dong-Kyu Jin Annals of Pediatric Endocrinology & Metabolism.2018; 23(4): 229. CrossRef - Rodzinna krzywica hipofosfatemiczna – opis przypadku i przegląd literatury
Agnieszka Jędzura, Omar Bjanid, Piotr Adamczyk, Krzysztof Plesiński, Karolina Klimaszewska-Adamus, Maria Szczepańska Pediatria Polska.2015; 90(5): 437. CrossRef - Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
|